Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
This article was originally published in The Tan Sheet
Executive Summary
The antigingivitis/antiplaque monograph should require that products containing a fixed combination of the essential oils menthol, thymol, methyl salicylate and eucalyptol be tested through both in vitro and in vivo test methods, Pfizer Consumer Healthcare maintains
You may also be interested in...
Combination Oral Health Care Products Safety Defended By Industry
Marketing of combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association. The group submitted comments to FDA on the subject Nov. 25
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking for OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register
Listerine comparability clinicals requirement urged by Warner-Lambert.
LISTERINE COMPARABILITY CLINICALS REQUIREMENT URGED by Warner-Lambert for products containing the same essential oil combination. At a May 27 meeting of FDA's Dental Plaque Subcommittee in Gaithersburg, Md., Warner-Lambert Consumer Healthcare R&D Dental Affairs Director Michael Barnett, DDS, suggested all marketers using the same essential oil active ingredients as Listerine be required to conduct six-month effectiveness studies because antimicrobial ingredients can be "adversely affected by excipients in a formulation."